Alkermes is a global biopharmaceutical company committed to developing innovative medicines for complex diseases.

Based in Dublin, Ireland, Alkermes focuses on creating treatments for psychiatric and neurological disorders, applying its expertise in neuroscience to improve patients’ lives. The company’s diverse product pipeline includes therapies for schizophrenia, bipolar disorder, and substance use disorders. Alkermes also partners with other organisations to enhance drug development processes.

Key products and services:

• Psychiatric and neurological treatments
• Olanzapine and samidorphan (Schizophrenia and Bipolar Disorder)
• ALKS 2680 (Narcolepsy treatment)
• Clinical trial services

Alkermes is dedicated to delivering real, positive impacts through the continued development of life-changing therapies.